S
MCRB icon

SignatureFD’s Seres Therapeutics MCRB Stock Holding History

SignatureFD’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150
Closed -$7.12K – 3210
2023
Q3 		$7.12K Buy
+150
New +$11.4K ﹤0.01% 2368
2023
Q2 		– Sell
-17
Closed -$1.92K – 3316
2023
Q1 		$1.92K Buy
+17
New +$1.84K ﹤0.01% 2815
2022
Q2 		– Sell
-16
Closed -$2K – 3254
2022
Q1 		$2K Buy
16
+12
+300% +$1.85K ﹤0.01% 2823
2021
Q4 		$1K Buy
+4
New +$636 ﹤0.01% 2949
2021
Q1 		– Sell
-2
Closed -$1K – 2798
2020
Q4 		$1K Buy
+2
New +$1.17K ﹤0.01% 2451

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SignatureFD's MCRB Position: Q4 2023 in Review

SignatureFD sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 150 shares — an estimated $7.12K sold.

SignatureFD first reported a position in MCRB in Q4 2020 and held it in 5 quarters. The position peaked at $7.12K in Q3 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • SignatureFD reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • SignatureFD sold 150 Seres Therapeutics shares in Q4 2023, an estimated $7.12K.
  • SignatureFD first reported a position in Seres Therapeutics in Q4 2020 and held it in 5 quarters.
  • SignatureFD's Seres Therapeutics position peaked at $7.12K in Q3 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.